Freenome, Inc. Cash and Restricted Cash
Freenome, Inc. (FRNM) had Cash and Restricted Cash of $437.37 thousand as of 2026-06-30, per its S-1 filed 2026-08-18.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-18
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $437.37K.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $567.18K.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $865.03K.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.18M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $437.37K S-1 · filed 2026-08-18 |
| 2026-03-31 | $567.18K S-4/A · filed 2026-06-11 |
| 2025-12-31 | $865.03K S-1 · filed 2026-08-18 |
| 2025-09-30 | $1.18M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.34M S-1 · filed 2026-08-18 |
| 2025-03-31 | $1.19M S-4/A · filed 2026-06-11 |
| 2024-12-31 | $1.13M S-1 · filed 2026-08-18 |
| 2024-09-30 | $1.21M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $1.29M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 |
| 2024-03-21 | $0.00 S-1 · filed 2026-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |